Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26869358 | 0.87 | LOX (0.41) | ALDH1A1L3MBTL1MEN1KMT2ACASP3 | |
| SCHEMBL26841429 | 0.84 | F2 (0.35) | ALDH1A1L3MBTL1MEN1KMT2ACA1 | |
| SCHEMBL24298714 | 0.82 | HDAC3 (0.42) | ALDH1A1L3MBTL1MEN1KMT2ACASP3 | |
| SCHEMBL26837763 | 0.80 | CASP3 (0.42) | ALDH1A1MEN1KMT2ARAB9ACASP3 | |
| SCHEMBL26846645 | 0.80 | WDR5 (0.35) | ALDH1A1L3MBTL1KMT2ACA1CA2 | |
| SCHEMBL26841506 | 0.79 | HSD11B1 (0.39) | ALDH1A1L3MBTL1HTTSMN1; SMN2GAA | |
| SCHEMBL26872601 | 0.79 | WDR5 (0.35) | ALDH1A1L3MBTL1MEN1KMT2ATSHR | |
| SCHEMBL26869586 | 0.78 | L3MBTL1 (0.35) | ALDH1A1L3MBTL1MEN1KMT2ATSHR | |
| SCHEMBL26831776 | 0.78 | EGFR (0.38) | ALDH1A1L3MBTL1MEN1KMT2AHTT | |
| SCHEMBL26876181 | 0.78 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382925-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ALDH1A1 4032/4885L3MBTL1 4201/4885MEN1 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.